Cubist Systematic Strategies’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $4.39M | Sell |
28,594
-213,445
| -88% | -$32.3M | 0.02% | 1039 |
|
|
2025
Q2 | $33.8M | Buy |
242,039
+124,682
| +106% | +$17.5M | 0.16% | 146 |
|
|
2025
Q1 | $17.3M | Buy |
117,357
+89,396
| +320% | +$12.9M | 0.1% | 249 |
|
|
2024
Q4 | $3.66M | Buy |
+27,961
| New | +$3.91M | 0.02% | 1010 |
|
|
2024
Q2 | – | Sell |
-44,821
| Closed | -$6.07M | – | 2983 |
|
|
2024
Q1 | $6.07M | Buy |
44,821
+40,432
| +921% | +$5.35M | 0.03% | 845 |
|
|
2023
Q4 | $591K | Sell |
4,389
-10,987
| -71% | -$1.43M | ﹤0.01% | 2434 |
|
|
2023
Q3 | $2.08M | Sell |
15,376
-15,921
| -51% | -$2.17M | 0.02% | 1342 |
|
|
2023
Q2 | $4.48M | Sell |
31,297
-2,945
| -9% | -$433K | 0.03% | 915 |
|
|
2023
Q1 | $4.75M | Buy |
34,242
+28,411
| +487% | +$3.82M | 0.03% | 976 |
|
|
2022
Q4 | $791K | Sell |
5,831
-8,932
| -61% | -$1.12M | ﹤0.01% | 2661 |
|
|
2022
Q3 | $1.62M | Buy |
14,763
+6,078
| +70% | +$771K | 0.01% | 2209 |
|
|
2022
Q2 | $1.15M | Buy |
8,685
+783
| +10% | +$103K | 0.01% | 2368 |
|
|
2022
Q1 | $1.05M | Buy |
7,902
+333
| +4% | +$39.9K | 0.01% | 1990 |
|
|
2021
Q4 | $882K | Buy |
7,569
+1,884
| +33% | +$222K | 0.01% | 2010 |
|
|
2021
Q3 | $683K | Sell |
5,685
-2,988
| -34% | -$348K | 0.01% | 1812 |
|
|
2021
Q2 | $1.04M | Sell |
8,673
-29,039
| -77% | -$3.19M | 0.01% | 1547 |
|
|
2021
Q1 | $3.75M | Buy |
37,712
+20,346
| +117% | +$2.05M | 0.05% | 597 |
|
|
2020
Q4 | $1.74M | Sell |
17,366
-22,922
| -57% | -$2.43M | 0.02% | 1043 |
|
|
2020
Q3 | $4.42M | Buy |
40,288
+13,145
| +48% | +$1.46M | 0.07% | 468 |
|
|
2020
Q2 | $2.87M | Buy |
27,143
+26,180
| +2,719% | +$2.7M | 0.05% | 597 |
|
|
2020
Q1 | $86K | Sell |
963
-7,584
| -89% | -$714K | ﹤0.01% | 1930 |
|
|
2019
Q4 | $852K | Buy |
+8,547
| New | +$805K | 0.02% | 1260 |
|
|
2019
Q3 | – | Sell |
-5,257
| Closed | -$434K | – | 2216 |
|
|
2019
Q2 | $434K | Sell |
5,257
-64,480
| -92% | -$5.06M | 0.01% | 1579 |
|
|
2019
Q1 | $5.64M | Buy |
69,737
+64,639
| +1,268% | +$5.09M | 0.18% | 103 |
|
|
2018
Q4 | $387K | Buy |
5,098
+4,198
| +466% | +$328K | 0.02% | 1119 |
|
|
2018
Q3 | $71K | Sell |
900
-8,225
| -90% | -$622K | ﹤0.01% | 1655 |
|
|
2018
Q2 | $641K | Sell |
9,125
-4,038
| -31% | -$291K | 0.03% | 670 |
|
|
2018
Q1 | $921K | Buy |
13,163
+9,621
| +272% | +$666K | 0.05% | 474 |
|
|
2017
Q4 | $246K | Buy |
3,542
+163
| +5% | +$11K | 0.01% | 1391 |
|
|
2017
Q3 | $229K | Sell |
3,379
-3,710
| -52% | -$234K | 0.01% | 1357 |
|
|
2017
Q2 | $483K | Sell |
7,089
-3,479
| -33% | -$227K | 0.03% | 767 |
|
|
2017
Q1 | $658K | Buy |
10,568
+495
| +5% | +$28.8K | 0.05% | 524 |
|
|
2016
Q4 | $550K | Sell |
10,073
-5,818
| -37% | -$330K | 0.04% | 621 |
|
|
2016
Q3 | $1.04M | Buy |
15,891
+2,919
| +23% | +$191K | 0.07% | 399 |
|
|
2016
Q2 | $783K | Sell |
12,972
-3,554
| -22% | -$206K | 0.05% | 549 |
|
|
2016
Q1 | $931K | Buy |
16,526
+10,257
| +164% | +$616K | 0.05% | 497 |
|
|
2015
Q4 | $426K | Sell |
6,269
-9,516
| -60% | -$624K | 0.02% | 908 |
|
|
2015
Q3 | $1M | Buy |
15,785
+4,544
| +40% | +$299K | 0.05% | 583 |
|
|
2015
Q2 | $716K | Sell |
11,241
-8,815
| -44% | -$604K | 0.04% | 756 |
|
|
2015
Q1 | $1.37M | Buy |
20,056
+17,960
| +857% | +$1.25M | 0.07% | 429 |
|
|
2014
Q4 | $148K | Buy |
2,096
+32
| +2% | +$2.29K | 0.01% | 1603 |
|
|
2014
Q3 | $147K | Sell |
2,064
-453
| -18% | -$33.2K | 0.01% | 1467 |
|
|
2014
Q2 | $187K | Buy |
+2,517
| New | +$182K | 0.01% | 1195 |
|
Other funds holding AZN
Cubist Systematic Strategies's AZN Position: Q3 2025 in Review
Cubist Systematic Strategies reduced its AstraZeneca (AZN) stake by 88% in Q3 2025, selling an estimated $32.3M and leaving 28,594 shares worth $4.39M. The position accounts for 0.02% of the portfolio, ranked #1039.
Cubist Systematic Strategies first reported a position in AZN in Q2 2014 and has held it in 43 quarters since. The position peaked at $33.8M in Q2 2025. 1,287 funds tracked by Wall St. Rank hold AZN as of Q3 2025.
- Cubist Systematic Strategies held 28,594 shares of AstraZeneca worth $4.39M as of Q3 2025.
- Cubist Systematic Strategies sold 213,445 AstraZeneca shares in Q3 2025, an estimated $32.3M.
- AstraZeneca made up 0.02% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1039 holding.
- Cubist Systematic Strategies first reported a position in AstraZeneca in Q2 2014 and has held it in 43 quarters since.
- Cubist Systematic Strategies's AstraZeneca position peaked at $33.8M in Q2 2025.
- 1,287 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.